Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2020-02-28

Original market date: See footnote 1

2020-02-28

Product name:

GLN-OLMESARTAN HCTZ

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02475707

Product Monograph/Veterinary Labelling:

Date: 2021-07-15 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

GLENMARK PHARMACEUTICALS CANADA INC.
1600 Steeles Ave. W., Suite 407
Concord
Ontario
Canada L4K 4M2

Class:

Human

Dosage form(s):

Tablet

Route(s) of administration:

Oral

Number of active ingredient(s):

2

Schedule(s):

Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

40:28.20  ,  24:32.08 

Anatomical Therapeutic Chemical (ATC): See footnote 4

C09DA08 OLMESARTAN MEDOXOMIL AND DIURETICS

Active ingredient group (AIG) number:See footnote5

0252502001

List of active ingredient(s)
Active ingredient(s) Strength
HYDROCHLOROTHIAZIDE 12.5 MG
OLMESARTAN MEDOXOMIL 20 MG
Version 4.0.2
Date modified: